Skip to content
  • Change font size
    • Original
    • Large
    • Extra large
CLARICO Study
  • Living with Primary Photoreceptor Disease
  • About the Study Drug
  • Study Eligibility
  • Study Details
  • Living with Primary Photoreceptor Disease
  • About the Study Drug
  • Study Eligibility
  • Study Details
find out more
find out more

  • Extended Evaluation Period

OpCT-001 is currently being studied and is not approved for use in any country.

The sponsor of the CLARICO study is BlueRock Therapeutics.

BlueRock Therapeutics
238 Main Street, 3rd Floor
Cambridge, MA 02142

Change font size
  • Original
  • Large
  • Extra Large
  • Privacy policy
  • Terms of use
  • Accessibility

MED-CA-OPH-2500001v2 (12/25)

© Copyright 2026  |  BlueRock Therapeutics  |  All Rights Reserved

Page load link
Go to Top